Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2018 /
Improved OS with obinutuzumab in the CLL11 study

14th - 17th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.18
Views: 678
Rating:

Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany

Dr Goede presents data at EHA 23 from a final analysis of treating CLL with obinutuzumab in place of rituximab alongside chlorambucil chemotherapy.

He outlines the previously reported data, culminating in the final analysis showing an improved progression-free survival and improved overall survival.

Overall, Dr Goede recommends this as a new standard of care for these patients.

For more on these findings, watch his interview with ecancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation